Precision BioSciences Announces $50 Million Offering of Common Stock

DURHAM, N.C. --(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a

Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

- Precision to Receive $75 Million Upfront for a Single Target; Precision Eligible to Receive up to an Additional $1.4 Billion in Milestones and Tiered Royalties on Sales of Licensed Products - Precision to Develop a Single ARCUS ® Nuclease Designed for Safe and Efficient In Vivo Gene Insertion -

Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population

PBCAR0191 Achieved 100% Response Rate (ORR), 73% Complete Response (CR) Rate and 50% Durable Response Greater than Six Months Among Evaluable CAR T Relapsed Subjects PBCAR0191 Achieved Peak CAR T Cell Expansion Matching Data from Autologous CAR T Peak Expansion in Long Term Durable Responders

Precision BioSciences to Provide an Update on its Ongoing Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on Wednesday, June 8, 2022

DURHAM, N.C. --(BUSINESS WIRE)--Jun. 3, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will share an update on its allogeneic CAR T

Precision BioSciences to Participate in Upcoming Jefferies Healthcare Conference

DURHAM, N.C. --(BUSINESS WIRE)--Jun. 3, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Healthcare

Precision BioSciences Appoints Melinda Brown to Board of Directors

New Director Brings Proven Financial and Leadership Experience Fifth Director Added to the Board of Directors Since April 2021 DURHAM, N.C. --(BUSINESS WIRE)--May 31, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic

Precision BioSciences Appoints Juli Blanche as Chief People Officer

New Senior Executive Brings 25 Years of Human Resources Leadership and Pharma Industry Experience DURHAM, N.C. --(BUSINESS WIRE)--May 23, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene

Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection

- ARCUS Genome Editing Achieved Substantial Reductions in both cccDNA and Hepatitis B Surface Antigen (HBsAg), 85% and 77% respectively, in HBV-infected Primary Human Hepatocytes (PHH) - Significant Decrease in HBsAg and High On-target Editing Achieved in Novel Mouse and Non-human Primate Models

Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting

Multiple Oral Presentations and Posters to Demonstrate Differentiated Attributes of ARCUS® Genome Editing Platform for Efficient Gene Insertion and Gene Knockout New Primary Hyperoxaluria Type 1 (PH1) Preclinical Data Demonstrate a Robust ARCUS Nuclease Optimization Process Leading to 98% Knockdown

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C. --(BUSINESS WIRE)--May 12, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on May 6, 2022 , the Compensation Committee of Precision’s

Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update

- PBCAR0191, PBCAR19B and PBCAR269A Allogeneic CAR T Program Updates Planned for June 2022 - Three Wholly Owned In Vivo Gene Editing Programs Progressing Toward IND or CTA in the Next Three Years - Preclinical In Vivo Gene Editing Data for Primary Hyperoxaluria Type 1 and Chronic Hepatitis B

Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting

- Accepted abstracts to be presented as oral presentations and posters highlight preclinical development progress for ARCUS ® gene editing therapies DURHAM, N.C. --(BUSINESS WIRE)--May 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ®

Precision BioSciences to Report First Quarter 2022 Financial Results on May 9, 2022

Company to Participate in the H.C. Wainwright Global Investment Conference on May 24, 2022 DURHAM, N.C. --(BUSINESS WIRE)--May 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

- Advancing ARCUS® Platform by Developing In Vivo Gene Editing Programs for Genetic Diseases and Ex Vivo CAR T Therapies for Hematologic Malignancies - Presented Allogeneic CAR T Clinical Data at the American Society of Hematology Meeting Showing High Response Rates to PBCAR0191 in Heavily Treated

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2021 Results on March 15, 2022

DURHAM, N.C. --(BUSINESS WIRE)--Mar. 8, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the fourth quarter and